4.6 Article

Genome-Wide Transcriptional Profiling Reveals MicroRNA-Correlated Genes and Biological Processes in Human Lymphoblastoid Cell Lines

期刊

PLOS ONE
卷 4, 期 6, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0005878

关键词

-

资金

  1. NCI NIH HHS [R21 CA126786, R21 CA126786-02, CA91956, P50 CA091956, CA126786] Funding Source: Medline

向作者/读者索取更多资源

Background: Expression level of many genes shows abundant natural variation in human populations. The variations in gene expression are believed to contribute to phenotypic differences. Emerging evidence has shown that microRNAs (miRNAs) are one of the key regulators of gene expression. However, past studies have focused on the miRNA target genes and used loss-or gain-of-function approach that may not reflect natural association between miRNA and mRNAs. Methodology/Principal Findings: To examine miRNA regulatory effect on global gene expression under endogenous condition, we performed pair-wise correlation coefficient analysis on expression levels of 366 miRNAs and 14,174 messenger RNAs (mRNAs) in 90 immortalized lymphoblastoid cell lines, and observed significant correlations between the two species of RNA transcripts. We identified a total of 7,207 significantly correlated miRNA-mRNA pairs (false discovery rate q<0.01). Of those, 4,085 pairs showed positive correlations while 3,122 pairs showed negative correlations. Gene ontology analyses on the miRNA-correlated genes revealed significant enrichments in several biological processes related to cell cycle, cell communication and signal transduction. Individually, each of three miRNAs (miR-331, -98 and -33b) demonstrated significant correlation with the genes in cell cycle-related biological processes, which is consistent with important role of miRNAs in cell cycle regulation. Conclusions/Significance: This study demonstrates feasibility of using naturally expressed transcript profiles to identify endogenous correlation between miRNA and miRNA. By applying this genome-wide approach, we have identified thousands of miRNA-correlated genes and revealed potential role of miRNAs in several important cellular functions. The study results along with accompanying data sets will provide a wealth of high-throughput data to further evaluate the miRNA-regulated genes and eventually in phenotypic variations of human populations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study

Paul Y. Takahashi, Euijung Ryu, Suzette J. Bielinski, Matthew Hathcock, Gregory D. Jenkins, James R. Cerhan, Janet E. Olson

Summary: This study found no association between 10 well-established pharmacogenomics phenotypes and hospitalization or ED visits. Traditional risk factors like age and self-rated health were more predictive of hospitalization and/or ED visits than pharmacogenomics information.

PHARMACOGENOMICS & PERSONALIZED MEDICINE (2021)

Article Oncology

High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)

Joshua C. Pritchett, Zhi-Zhang Yang, Hyo Jin Kim, Jose C. Villasboas, Xinyi Tang, Shahrzad Jalali, James R. Cerhan, Andrew L. Feldman, Stephen M. Ansell

Summary: AITL is an aggressive lymphoid malignancy with a unique tumor microenvironment characterized by a minority population of malignant TFH cells and a diverse infiltrate of immune cells. Non-malignant populations within the TME, such as B cells and CD8+ T cells, are increasingly recognized for their potential role in AITL biology. These non-malignant populations exhibit specific expression patterns that may contribute to the understanding of AITL pathogenesis.

LEUKEMIA (2022)

Editorial Material Hematology

A (modifiable) way to better Hodgkin lymphoma survivorship?

James R. Cerhan

Summary: In this article, Williams et al. provide a clearer perspective on the additional burden of neurocognitive, psychosocial, and quality of life impairments faced by long-term survivors of childhood Hodgkin lymphoma. The authors also identify potentially modifiable factors that could help prevent or reduce adverse outcomes.
Article Oncology

B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS

Sophia S. Wang, Claire M. Vajdic, Martha S. Linet, Susan L. Slager, Jenna Voutsinas, Alexandra Nieters, Delphine Casabonne, James R. Cerhan, Wendy Cozen, Graciela Alarcon, Otoniel Martinez-Maza, Elizabeth E. Brown, Paige M. Bracci, Jennifer Turner, Henrik Hjalgrim, Parveen Bhatti, Yawei Zhang, Brenda M. Birmann, Christopher R. Flowers, Ora Palliel, Elizabeth A. Holly, Eleanor Kane, Dennis Weisenburger, Marc Maynadie, Pierluigi Cocco, Lenka Foretova, Elizabeth Crabb Breen, Qing Lan, Angela Brooks-Wilson, Anneclaire J. De Roos, Martyn T. Smith, Eve Roman, Paoloa Boffetta, Anne Kricker, Tongzhang Zheng, Christine F. Skibola, Jacqueline Clavel, Alain Monnereau, Stephen J. Chanock, Nathaniel Rothman, Yolanda Benavente, Patricia Hartge, Karin E. Smedby

Summary: This study suggests that polygenic risk scores (PRS) constructed from currently known subtype-specific loci may not capture biological pathways shared with autoimmune conditions. Targeted genetic screening (PRS) among populations with autoimmune conditions may help identify individuals at highest risk for DLBCL and enable early detection.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2022)

Article Oncology

PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts

Sanjal H. Desai, Levi D. Pederson, Betsy Laplant, Raphael Mwangi, Matthew J. Maurer, Jason R. Young, William R. Macon, Rebecca L. King, Yucai Wang, James R. Cerhan, Andrew L. Feldman, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski

Summary: This study found that PET2 after two cycles of chemotherapy can predict the risk of disease progression and death in patients with diffuse large B cell lymphoma. PET2-guided risk-adapted strategies may improve outcomes for these patients.

BLOOD CANCER JOURNAL (2022)

Article Oncology

Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care

Surbhi Sidana, Cristine Allmer, Melissa C. Larson, Amylou Dueck, Kathleen Yost, Rahma Warsame, Gita Thanarajasingam, James R. Cerhan, Jonas Paludo, S. Vincent Rajkumar, Thomas M. Habermann, Grzegorz S. Nowakowski, Yi Lin, Morie A. Gertz, Thomas Witzig, Angela Dispenzieri, Wilson Gonsalves, Stephen M. Ansell, Carrie A. Thompson, Shaji K. Kumar

Summary: Patients treated on CTs reported similar QoL and quality of care compared to the non-CT group, but both groups experienced increasing financial burden over time.

JCO ONCOLOGY PRACTICE (2022)

Review Hematology

Utilization of real-world data in assessing treatment effectiveness for diffuse large B-cell lymphoma

Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn

Summary: Comparative effectiveness studies using real-world data can provide complementary evidence on treatment effectiveness. By balancing baseline covariates using propensity score methods, closely matched patient-level cohorts can be generated for robust comparative analyses.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Hematology

Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma

Juan Pablo Alderuccio, Isildinha M. Reis, Thomas M. Habermann, Brian K. Link, Catherine Thieblemont, Annarita Conconi, Melissa C. Larson, Luciano Cascione, Wei Zhao, James R. Cerhan, Emanuele Zucca, Izidore S. Lossos

Summary: The study developed and validated a new prognostic index, the Revised mucosa-associated lymphoid tissue International Prognostic Index (Revised MALT-IPI), which is centered on disease characteristics and provides robust risk stratification, identifying a group of patients characterized by earlier progression of EMZL.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Article Oncology

Physical activity and the risk of non-Hodgkin lymphoma subtypes: A pooled analysis

Terry Boyle, Geffen Kleinstern, Paige M. Bracci, James R. Cerhan, Yolanda Benavente, Delphine Casabonne, Brian C-H Chiu, Thomas M. Habermann, Elizabeth A. Holly, Mark Liebow, Aaron Norman, Ora Paltiel, Dennis Robinson, Nathaniel Rothman, Rania Abu Seir, Susan L. Slager, Paul J. Villeneuve, Sophia S. Wang, Dennis D. Weisenburger, John J. Spinelli

Summary: This study, which pooled data from nine case-control studies, found that moderate-to-vigorous intensity physical activity can reduce the risk of non-Hodgkin lymphoma.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Hematology

Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis

Sanjal H. Desai, Raphael Mwangi, Wern Lynn Ng, Rebecca L. King, Matthew J. Maurer, James R. Cerhan, Andrew L. Feldman, Umar Farooq, Eric Mou, Thomas M. Habermann, Carrie A. Thompson, Yucai Wang, Thomas E. Witzig, Grzegorz S. Nowakowski

Summary: This observational study found that patients with DLBCL who underwent CNB had poor-risk features, worse outcomes, and inadequate tissue for molecular analyses compared to those who underwent EB. The increasing tissue requirements of biomarker-driven clinical trials may result in the exclusion of high-risk DLBCL patients who need novel agents.

BLOOD ADVANCES (2022)

Letter Oncology

The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis

Sameer A. Parikh, Sara J. Achenbach, Kari G. Rabe, Aaron D. Norman, Nicholas J. Boddicker, Janet E. Olson, Timothy G. Call, James R. Cerhan, Celine M. Vachon, Neil E. Kay, Esteban Braggio, Curtis A. Hanson, Susan L. Slager, Tait D. Shanafelt

BLOOD CANCER JOURNAL (2022)

Article Oncology

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era

Cristina Correia, Matthew J. J. Maurer, Samantha J. J. McDonough, Paula A. A. Schneider, Paige E. E. Ross, Anne J. J. Novak, Andrew L. L. Feldman, James R. R. Cerhan, Susan L. L. Slager, Thomas E. E. Witzig, Bruce W. W. Eckloff, Hu Li, Grzegorz S. S. Nowakowski, Scott H. H. Kaufmann

Summary: The identification of follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. In a study on newly diagnosed FLs, BCL2 mutations with high variant allele frequency (VAF) were found to be associated with increased transformation risk and shorter event-free survival. However, other sequenced genes did not contribute significantly to the prognostic value of the panel. Nonsynonymous BCL2 mutations with VAF = 20% were consistently associated with decreased event-free survival and overall survival.

BLOOD CANCER JOURNAL (2023)

Article Oncology

Fecal Microbiota Restoration Modulates the Microbiome in Inflammation-Driven Colorectal Cancer

Travis J. Gates, Ce Yuan, Mihir Shetty, Thomas Kaiser, Andrew C. Nelson, Aastha Chauhan, Timothy K. Starr, Christopher Staley, Subbaya Subramanian

Summary: Inflammation of the colon (colitis) increases the risk of colorectal cancers, and gut microbiota may be involved in cancer development. Manipulating the bacteria community in the colon could be a potential way to prevent cancer. A study using mice found that transferring bacteria from healthy mice to those with colitis increased the presence of Akkermansia, which may alleviate colon inflammation, while untreated mice had an increase in other bacteria types, such as Anaeroplasma and Alistipes, which could contribute to inflammation. These findings suggest that specific bacteria types may help reduce colon inflammation and prevent cancer.

CANCERS (2023)

Article Environmental Sciences

Modeling historic neighborhood deprivation and non-Hodgkin lymphoma risk

Joseph Boyle, Mary H. Ward, James R. Cerhan, Nathaniel Rothman, David C. Wheeler

Summary: Many studies have found associations between neighborhood deprivation and disease, emphasizing the importance of social determinants of health. However, when studying diseases with long latency periods such as cancers, considering the timing of exposures for deprivation becomes more important.

ENVIRONMENTAL RESEARCH (2023)

Editorial Material Oncology

Advancing Cancer Immunotherapy: From Molecular Mechanisms to Clinical Applications

Xianda Zhao, Timothy Starr, Subbaya Subramanian

CANCERS (2023)

暂无数据